180 related articles for article (PubMed ID: 32572959)
1. GSK3β suppression inhibits MCL1 protein synthesis in human acute myeloid leukemia cells.
Lee YC; Shi YJ; Wang LJ; Chiou JT; Huang CH; Chang LS
J Cell Physiol; 2021 Jan; 236(1):570-586. PubMed ID: 32572959
[TBL] [Abstract][Full Text] [Related]
2. NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells.
Chiou JT; Huang NC; Huang CH; Wang LJ; Lee YC; Shi YJ; Chang LS
J Cell Physiol; 2021 Nov; 236(11):7356-7375. PubMed ID: 33982799
[TBL] [Abstract][Full Text] [Related]
3. ABT-263-induced MCL1 upregulation depends on autophagy-mediated 4EBP1 downregulation in human leukemia cells.
Lee YC; Wang LJ; Huang CH; Shi YJ; Chang LS
Cancer Lett; 2018 Sep; 432():191-204. PubMed ID: 29913235
[TBL] [Abstract][Full Text] [Related]
4. Cytarabine-induced destabilization of MCL1 mRNA and protein triggers apoptosis in leukemia cells.
Chiou JT; Hsu CC; Hong YC; Lee YC; Chang LS
Biochem Pharmacol; 2023 May; 211():115494. PubMed ID: 36924905
[TBL] [Abstract][Full Text] [Related]
5. Amsacrine-induced apoptosis of human leukemia U937 cells is mediated by the inhibition of AKT- and ERK-induced stabilization of MCL1.
Lee YC; Chen YJ; Huang CH; Chang LS
Apoptosis; 2017 Mar; 22(3):406-420. PubMed ID: 27757735
[TBL] [Abstract][Full Text] [Related]
6. BCL2L1 inhibitor A-1331852 inhibits MCL1 transcription and triggers apoptosis in acute myeloid leukemia cells.
Chiou JT; Wu YY; Lee YC; Chang LS
Biochem Pharmacol; 2023 Sep; 215():115738. PubMed ID: 37562509
[TBL] [Abstract][Full Text] [Related]
7. ONC212 enhances YM155 cytotoxicity by triggering SLC35F2 expression and NOXA-dependent MCL1 degradation in acute myeloid leukemia cells.
Chiou JT; Chang LS
Biochem Pharmacol; 2024 Jun; 224():116242. PubMed ID: 38679209
[TBL] [Abstract][Full Text] [Related]
8. BCL2 inhibitor ABT-199 and BCL2L1 inhibitor WEHI-539 coordinately promote NOXA-mediated degradation of MCL1 in human leukemia cells.
Chiou JT; Lee YC; Wang LJ; Chang LS
Chem Biol Interact; 2022 Jul; 361():109978. PubMed ID: 35561756
[TBL] [Abstract][Full Text] [Related]
9. Synergistic cytotoxicity of decitabine and YM155 in leukemia cells through upregulation of SLC35F2 and suppression of MCL1 and survivin expression.
Chiou JT; Chang LS
Apoptosis; 2024 Apr; 29(3-4):503-520. PubMed ID: 38066391
[TBL] [Abstract][Full Text] [Related]
10. The suppressive effect of arsenic trioxide on TET2-FOXP3-Lyn-Akt axis-modulated MCL1 expression induces apoptosis in human leukemia cells.
Chen YJ; Huang CH; Shi YJ; Lee YC; Wang LJ; Chang LS
Toxicol Appl Pharmacol; 2018 Nov; 358():43-55. PubMed ID: 30213730
[TBL] [Abstract][Full Text] [Related]
11. Autophagic HuR mRNA degradation induces survivin and MCL1 downregulation in YM155-treated human leukemia cells.
Chiou JT; Lee YC; Huang CH; Shi YJ; Wang LJ; Chang LS
Toxicol Appl Pharmacol; 2020 Jan; 387():114857. PubMed ID: 31837377
[TBL] [Abstract][Full Text] [Related]
12. CREB/Sp1-mediated MCL1 expression and NFκB-mediated ABCB1 expression modulate the cytotoxicity of daunorubicin in chronic myeloid leukemia cells.
Chiou JT; Huang CH; Wu TH; Wang LJ; Lee YC; Huang PW; Chang LS
Toxicol Appl Pharmacol; 2022 Jan; 435():115847. PubMed ID: 34963561
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Sp1-mediated survivin and MCL1 expression cooperates with SLC35F2 and myeloperoxidase to modulate YM155 cytotoxicity to human leukemia cells.
Chiou JT; Lee YC; Huang CH; Wang LJ; Shi YJ; Chang LS
Biochem Pharmacol; 2021 Jun; 188():114544. PubMed ID: 33831396
[TBL] [Abstract][Full Text] [Related]
14. MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.
Lu JW; Lin YM; Lai YL; Chen CY; Hu CY; Tien HF; Ou DL; Lin LI
Med Oncol; 2015 Jul; 32(7):206. PubMed ID: 26087957
[TBL] [Abstract][Full Text] [Related]
15. GSK3α/β: A Novel Therapeutic Target for Neuroendocrine Tumors.
Aristizabal Prada ET; Weis C; Orth M; Lauseker M; Spöttl G; Maurer J; Grabowski P; Grossman A; Auernhammer CJ; Nölting S
Neuroendocrinology; 2018; 106(4):335-351. PubMed ID: 28968593
[TBL] [Abstract][Full Text] [Related]
16. Albendazole-Induced SIRT3 Upregulation Protects Human Leukemia K562 Cells from the Cytotoxicity of MCL1 Suppression.
Wang LJ; Liou LR; Shi YJ; Chiou JT; Lee YC; Huang CH; Huang PW; Chang LS
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486166
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and ex vivo evaluation of carbon-11 labelled N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea ([11C]AR-A014418): a radiolabelled glycogen synthase kinase-3beta specific inhibitor for PET studies.
Vasdev N; Garcia A; Stableford WT; Young AB; Meyer JH; Houle S; Wilson AA
Bioorg Med Chem Lett; 2005 Dec; 15(23):5270-3. PubMed ID: 16202587
[TBL] [Abstract][Full Text] [Related]
18. Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma.
Miyashita K; Kawakami K; Nakada M; Mai W; Shakoori A; Fujisawa H; Hayashi Y; Hamada J; Minamoto T
Clin Cancer Res; 2009 Feb; 15(3):887-97. PubMed ID: 19188159
[TBL] [Abstract][Full Text] [Related]
19. Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition.
Tambe M; Karjalainen E; Vähä-Koskela M; Bulanova D; Gjertsen BT; Kontro M; Porkka K; Heckman CA; Wennerberg K
Leukemia; 2020 Dec; 34(12):3186-3196. PubMed ID: 32651543
[TBL] [Abstract][Full Text] [Related]
20. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
